Administration of baricitinib in T2D patients to suppress JAK downstream of IL-6R showed acceptable safety and a moderate improvement of the kidney function reflected by reduced albuminuria (142, 143). The gene discussed is IL6R; the disease is type 2 diabetes mellitus.